Viral Vector News and Research

RSS
Viral Vector is a type of virus used in cancer therapy. The virus is changed in the laboratory and cannot cause disease. Viral vectors may produce tumor antigens (proteins found on a tumor cell) to stimulate an antitumor immune response in the body. Viral vectors may also be used to carry genes that can change cancer cells back to normal cells.
Oxford University and AstraZeneca release their COVID-19 vaccine results

Oxford University and AstraZeneca release their COVID-19 vaccine results

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

New understanding of glycan signatures of the SARS-COV-2 S1 spike protein

Repairing brain damage caused by MS

Repairing brain damage caused by MS

UH and CWRU announce Phase 3 trial of Astrazeneca's investigational COVID-19 vaccine

UH and CWRU announce Phase 3 trial of Astrazeneca's investigational COVID-19 vaccine

Phase 1 trial results of gorilla adenovirus vaccine for COVID-19

Phase 1 trial results of gorilla adenovirus vaccine for COVID-19

Design of an mRNA SARS-CoV-2 vaccine encapsulated in lipid nanoparticles

Design of an mRNA SARS-CoV-2 vaccine encapsulated in lipid nanoparticles

Mass production of SARS-CoV-2 ORF8 protein using a chemical-inducible system in tobacco BY-2 cells

Mass production of SARS-CoV-2 ORF8 protein using a chemical-inducible system in tobacco BY-2 cells

People infected with other types of coronaviruses may have less severe COVID-19 infection

People infected with other types of coronaviruses may have less severe COVID-19 infection

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

J&J's COVID-19 vaccine shows potent immune response in phase 2 human trial

OXGENE launches a scalable, plasmid-free manufacturing system for AAV

OXGENE launches a scalable, plasmid-free manufacturing system for AAV

Oxford University and AstraZeneca resume COVID-19 vaccine trial

Oxford University and AstraZeneca resume COVID-19 vaccine trial

Effective, simple, safe self-amplifying RNA vaccines

Effective, simple, safe self-amplifying RNA vaccines

AstraZeneca COVID-19 vaccine trial paused due to suspected adverse reaction

AstraZeneca COVID-19 vaccine trial paused due to suspected adverse reaction

Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine

Early-phase Russian trials reveal safety and immunogenicity of two formulations of a two-part vaccine

Promising new candidate 'virus-like particle' vaccine for COVID-19

Promising new candidate 'virus-like particle' vaccine for COVID-19

New treatment approach strengthens motor function and muscle of aged mice

New treatment approach strengthens motor function and muscle of aged mice

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

Targeting SARS-CoV-2 with off-the-shelf CAR-NK cells

De novo designed SARS-CoV-2 nanoparticle vaccine

De novo designed SARS-CoV-2 nanoparticle vaccine

Exciting cost-effective SARS-CoV-2 vaccine candidate using Newcastle disease

Exciting cost-effective SARS-CoV-2 vaccine candidate using Newcastle disease

Monash University researchers pave way for affordable immunotherapies

Monash University researchers pave way for affordable immunotherapies